These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 21416169)

  • 1. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.
    Cysique LA; Brew BJ
    J Neurovirol; 2011 Apr; 17(2):176-83. PubMed ID: 21416169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.
    Heaton RK; Clifford DB; Franklin DR; Woods SP; Ake C; Vaida F; Ellis RJ; Letendre SL; Marcotte TD; Atkinson JH; Rivera-Mindt M; Vigil OR; Taylor MJ; Collier AC; Marra CM; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Abramson I; Gamst A; Fennema-Notestine C; Jernigan TL; Wong J; Grant I;
    Neurology; 2010 Dec; 75(23):2087-96. PubMed ID: 21135382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.
    Temereanca A; Ene L; Rosca A; Diaconu CC; Luca A; Burlacu R; Radoi R; Bulacu-Talnariu A; Marcotte TD; Achim CL; Ruta S
    AIDS Res Hum Retroviruses; 2020 May; 36(5):367-372. PubMed ID: 31476875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychological Assessment of 412 HIV-Infected Individuals in São Paulo, Brazil.
    Gascón MRP; Vidal JE; Mazzaro YM; Smid J; Marcusso RMN; Capitão CG; Coutinho EM; Benute GRG; De Lucia MCS; de Oliveira ACP
    AIDS Patient Care STDS; 2018 Jan; 32(1):1-8. PubMed ID: 29323557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study.
    Kelly CM; van Oosterhout JJ; Ngwalo C; Stewart RC; Benjamin L; Robertson KR; Khoo S; Allain TJ; Solomon T
    PLoS One; 2014; 9(6):e98962. PubMed ID: 24915530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.
    Bunupuradah T; Chetchotisakd P; Jirajariyavej S; Valcour V; Bowonwattanuwong C; Munsakul W; Klinbuayaem V; Prasithsirikul W; Sophonphan J; Mahanontharit A; Hirschel B; Bhakeecheep S; Ruxrungtham K; Ananworanich J;
    J Neurovirol; 2012 Dec; 18(6):479-87. PubMed ID: 22993101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurocognitive Impairment in a Chronically Well-Suppressed HIV-Infected Population: The Dutch TREVI Cohort Study.
    van den Dries LWJ; Wagener MN; Jiskoot LC; Visser M; Robertson KR; Adriani KS; van Gorp ECM
    AIDS Patient Care STDS; 2017 Aug; 31(8):329-334. PubMed ID: 28753395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study.
    Lawler K; Mosepele M; Ratcliffe S; Seloilwe E; Steele K; Nthobatsang R; Steenhoff A
    J Int AIDS Soc; 2010 Apr; 13():15. PubMed ID: 20406460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection.
    Childers ME; Woods SP; Letendre S; McCutchan JA; Rosario D; Grant I; Mindt MR; Ellis RJ;
    J Neurovirol; 2008 Nov; 14(6):550-7. PubMed ID: 19016380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?
    Muñoz-Moreno JA; Fumaz CR; Prats A; Ferrer MJ; Negredo E; Pérez-Alvarez N; Moltó J; Gómez G; Garolera M; Clotet B
    J Neurovirol; 2010 May; 16(3):208-18. PubMed ID: 20450380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion.
    Marcotte TD; Deutsch R; McCutchan JA; Moore DJ; Letendre S; Ellis RJ; Wallace MR; Heaton RK; Grant I;
    Arch Neurol; 2003 Oct; 60(10):1406-12. PubMed ID: 14568811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in HIV RNA and CD4 cell count after acute HCV infection in chronically HIV-infected individuals.
    Gras L; de Wolf F; Smit C; Prins M; van der Meer JT; Vanhommerig JW; Zwinderman AH; Schinkel J; Geskus RB;
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):536-42. PubMed ID: 25559595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.
    Ciccarelli N; Fabbiani M; Di Giambenedetto S; Fanti I; Baldonero E; Bracciale L; Tamburrini E; Cauda R; De Luca A; Silveri MC
    Neurology; 2011 Apr; 76(16):1403-9. PubMed ID: 21502598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic network connectivity abnormalities in HIV-infected individuals over age 60.
    Guha A; Wang L; Tanenbaum A; Esmaeili-Firidouni P; Wendelken LA; Busovaca E; Clifford K; Desai A; Ances BM; Valcour V
    J Neurovirol; 2016 Feb; 22(1):80-7. PubMed ID: 26265137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection.
    Evering TH; Applebaum A; La Mar M; Garmon D; Dorfman D; Markowitz M
    AIDS; 2016 Jan; 30(2):203-10. PubMed ID: 26684817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.
    Tozzi V; Balestra P; Salvatori MF; Vlassi C; Liuzzi G; Giancola ML; Giulianelli M; Narciso P; Antinori A
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):56-63. PubMed ID: 19731418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy.
    Cysique LA; Vaida F; Letendre S; Gibson S; Cherner M; Woods SP; McCutchan JA; Heaton RK; Ellis RJ
    Neurology; 2009 Aug; 73(5):342-8. PubMed ID: 19474412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.
    Carvalhal A; Gill MJ; Letendre SL; Rachlis A; Bekele T; Raboud J; Burchell A; Rourke SB;
    J Neurovirol; 2016 Jun; 22(3):349-57. PubMed ID: 26572786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognitive symptoms and impairment in an HIV community clinic.
    Kim DH; Jewison DL; Milner GR; Rourke SB; Gill MJ; Power C
    Can J Neurol Sci; 2001 Aug; 28(3):228-31. PubMed ID: 11513341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment.
    Tozzi V; Balestra P; Galgani S; Narciso P; Ferri F; Sebastiani G; D'Amato C; Affricano C; Pigorini F; Pau FM; De Felici A; Benedetto A
    AIDS; 1999 Oct; 13(14):1889-97. PubMed ID: 10513647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.